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Objective. To determine whether men with rheumatoid arthritis (RA) are more likely to achieve remission compared to
women.
Methods. RA patients enrolled in the Consortium of Rheumatology Researchers of North America (CORRONA) cohort
between October 2001 and January 2010 were selected for the present analyses. Detailed clinical, demographic, and drug
utilization data were available at enrollment (baseline) and at subsequent followup visits. We examined the influence of sex
on the Clinical Disease Activity Index remission score (<2.8) using sustained remission or point remission as the primary
outcome measure in multivariate stepwise logistic regression models. We stratified the data by RA duration at baseline (<2
years or >2 years) to investigate whether RA duration had differential effects on remission in men and women.
Results. A total of 10,299 RA patients (2,406 men and 7,893 women) were available for this study. In both early and
established RA, women had more severe disease at baseline with worse disease activity measures, modified Health
Assessment Questionnaire disability index score, pain on a visual analog scale, and depression. Women were also more
likely to have been treated with disease-modifying antirheumatic drugs and anti–tumor necrosis factor therapy compared
to men. In the regression models, male sex was associated with sustained remission in early RA (odds ratio [OR] 1.38, 95%
confidence interval [95% CI] 1.07–1.78, P  0.01), but not in established RA. However, for point remission, an inverse
association was observed with male sex in established RA (OR 0.65, 95% CI 0.48–0.87, P  0.005) and not in early RA.
Conclusion. Within the large real-life CORRONA cohort of RA patients, men were more likely to achieve sustained
remission compared to women in early RA, although not in established RA.
INTRODUCTION
With recent advances in available therapies for rheuma-
toid arthritis (RA) and their effectiveness in management
of the disease (1), the goal of RA treatment has evolved
from a reduction in pain, despite ongoing inflammation
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and disability, to achievement and sustainability of dis-
ease remission (2). However, the ability to respond favor-
ably to treatment and achieve remission varies widely
between patients. Over the last few years, there has been a
growing interest in a possible role for sex in predicting
remission in RA.
A number of studies have reported better responses
(3–6) and/or increased remission (4,6–13) among men
compared to women in response to both biologic and
nonbiologic disease-modifying antirheumatic drugs
(DMARDs), while some did not find any association be-
tween sex and remission (14,15). Thus, although evidence
of increased remission among men is accumulating, it has
not firmly been established. Further, most of these studies
investigated remission at only one point in time, which
may not adequately reflect clinical remission.
In the present study, our goal was to examine the role of
sex as a potential predictor of remission in a large cohort of
patients with RA from the Consortium of Rheumatology
Researchers of North America (CORRONA). We wished to
test the hypothesis that male sex is a significant predictor
of remission in RA.
PATIENTS AND METHODS
Patients. The study population consisted of RA patients
enrolled in the prospective observational CORRONA co-
hort between October 1, 2001 and January 8, 2010. The
CORRONA network includes 268 participating academic
and community rheumatologists at 103 sites in 35 states
within the US. Details of the CORRONA network of re-
cruitment sites and cohort have been published elsewhere
(16). All patients who satisfied the 1987 American College
of Rheumatology (ACR) criteria for RA (17) and who were
being treated by participating rheumatologists were eligi-
ble for enrollment into the cohort. Ethical approval for the
study was obtained from institutional review boards of
participating academic recruitment sites and from a cen-
tral institutional review board for community-based pri-
vate recruitment sites. All patients provided written in-
formed consent prior to being enrolled in the cohort.
Data collected. Detailed clinical, demographic, and
drug utilization data were collected for each patient at
enrollment into the cohort (study baseline) and at subse-
quent routine followup visits at intervals of 3 months.
The data collected by the participating rheumatologists
included joint counts for 28 swollen (SJC28) and tender
joints (TJC28), physician global assessment (GA), presence
of radiographic erosions, rheumatoid factor (RF) seropos-
itivity, comorbidities, number of previous hospitaliza-
tions, and individual components of the ACR response
criteria. Drug utilization data were recorded for traditional
as well as biologic DMARDs. Patients also completed ques-
tionnaires that collected self-reported data on global
health assessment (patient GA), pain on a visual analog
scale (VAS), work status (full time, part time, not working
outside home, student, disabled, or retired), ethnicity, de-
pression prior to baseline, the modified Health Assessment
Questionnaire disability index (M-HAQ DI), and use of
prednisone and/or anti–tumor necrosis factor (anti-TNF)
therapy.
Disease activity scores. Disease activity was assessed as
follows: 1) the Disease Activity Score in 28 joints (DAS28)
count using 4 variables and the erythrocyte sedimentation
rate (ESR) (18) and 2) the Clinical Disease Activity Index
(CDAI) scores (19). Disease activity was computed as
DAS28  0.56TJC  0.28SJC
 0.70  lnESR  0.014GA
CDAI  SJC  TJC  physician GA in cm
 patient GA in cm
CDAI remission as the end point. The primary outcome
of interest, i.e., RA remission, was assessed based on CDAI
remission (score 2.8) (20). Patients were classified as
being in “sustained remission” if they were in CDAI re-
mission at any 2 consecutive visits after baseline that were
more than 2 months, and up to 6 months, apart. For those
patients who did not achieve sustained remission during
the study followup, we determined whether they achieved
“point remission.” Patients were considered to be in point
remission if they satisfied the CDAI remission criteria at
any single visit after baseline and, for reasons of reliability,
if the CDAI score at the remission visit was at least 2.0
units lower than at the previous and subsequent visits.
Since patients can often go in and out of remission at
different points in time, for each patient who satisfied the
point remission criteria in the present study, we chose to
include only the first instance of remission.
Statistical analysis. Baseline sex comparisons. All pa-
tients who had a diagnosis of RA at study baseline were
included in the analyses unless they had missing data on
sex, ethnicity, and/or CDAI scores at baseline, were in
CDAI remission at baseline, or had had a followup of 1
year since enrollment into the cohort. Baseline compari-
sons of disease characteristics and drug use between men
and women were performed using chi-square tests for
categorical variables and t-tests using a pooled or un-
pooled SE with Satterthwaite’s approximation for degrees
of freedom, as appropriate, for continuous variables.
Stepwise multivariate logistic regression. We examined
the influence of sex as the main explanatory variable (fe-
Significance & Innovations
● The present study investigates the influence of sex
on remission using sustained remission as the out-
come of interest, in contrast to previous studies
that used point remission.
● This study is the first to report that male sex is a
significant predictor for sustained remission in
early rheumatoid arthritis (RA), and not in estab-
lished RA.
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male sex as the referent category) on CDAI remission using
sustained remission as the primary outcome measure in
multivariate logistic regression models. Patients who did
not attain sustained remission but satisfied our point re-
mission criteria were excluded from these analyses. We
also performed a separate analysis for the patients who
achieved point but not sustained remission. For both sus-
tained remission and point remission, we used a stepwise
regression approach to assess which covariates contrib-
uted to the prediction model. Candidate covariates in-
cluded age, baseline CDAI score, ethnicity (white versus
nonwhite, with white as the reference group), RA dura-
tion, work status (full time versus part time/not working
outside home/student or being disabled/retired, with full
time as the reference group), self-reported depression prior
to baseline, prednisone use (yes or no), use of anti-TNF
therapy (yes or no), strong DMARD use (i.e., methotrexate,
leflunomide, sulfasalazine, azathioprine, cyclosporine, ta-
crolimus, gold, etc.), presence of subcutaneous nodules
(yes or no), pain on a VAS, and previous hospitalization
for RA (yes or no). Since the length of followup varied
between patients depending on when they were enrolled
in the cohort, and the chances of remission are likely to
increase with increasing length of followup, we also ad-
justed for “length of followup” in the regression models.
Further, although we stratified the data according to
whether the patients had duration of RA of at most 2 years
or more than 2 years, we adjusted for differences in RA
duration between patients within the strata.
RESULTS
Baseline comparisons between men and women. A to-
tal of 10,299 RA patients (2,406 men and 7,893 women)
who were not in remission at baseline were available for
the present analyses after we excluded patients who had
missing data on sex, ethnicity, or CDAI scores at baseline
(Figure 1). The demographic and clinical characteristics of
these patients at baseline are summarized by sex and RA
duration in Table 1. The patients were predominantly
white (82%). Overall, in both the early RA and estab-
lished RA groups, the men were older, and a significantly
larger proportion of men were married (80% versus 62%
[P  0.0001] for early RA and 77% versus 63% [P 
0.0001] for established RA) and/or were employed full
time (55% versus 44% [P  0.0001] for early RA and 40%
versus 32% [P  0.0001] for established RA) compared to
women.
Subcutaneous nodules and RF seropositivity were nu-
merically more common among men, whereas radio-
graphic erosions were more common among women; how-
ever, these differences were not statistically significant.
Disease activity measures were worse among women and
included mean  SD CDAI scores (18.7  13.5 versus
17.4  13.2 [P  0.02] for early RA; 16.6  12.3 versus
15.8  12.0 [P  0.0001] for established RA), mean  SD
tender joint counts (6.1  6.5 versus 4.9  6.0 [P  0.0001]
for early RA; 5.0  6.0 versus 4.4  5.6 [P  0.0004] for
established RA), mean  SD ESR (25.6  21.3 mm/hour
Figure 1. Selection of RA patients from the Consortium of Rheumatology Researchers of
North America (CORRONA) database. *  rheumatoid arthritis (RA) patients with non-
missing data for sex, ethnicity, and Clinical Disease Activity Index (CDAI) at baseline.
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versus 23.5  23.4 mm/hour [P  0.12] for early RA; 26.7
 22.0 mm/hour versus 20.3  19.6 mm/hour [P  0.0001]
for established RA), and mean  SD patient global health
(35.2  25.9 versus 32.6  25.4 [P  0.02] for early RA;
35.0  25.4 versus 32.9  24.5 [P  0.003] for established
RA). Swollen joint counts and morning stiffness were sim-
ilar between men and women. Mean  SD physician
global scores were higher among women (31.0  21.0
versus 29.5  20.9 [P  0.66] for early RA; 28.1  20.8
versus 26.8  20.2 [P  0.02] for established RA), as were
self-reported measures, including the mean  SD patient
pain VAS (37.8  27.0 versus 35.2  26.1 [P  0.02] for
early RA; 36.8  26.0 versus 34.1  24.9 [P  0.0001] for
established RA), the mean  SD M-HAQ DI (0.41  0.45
versus 0.36  0.45 [P  0.02] for early RA; 0.42  0.47
versus 0.35  0.43 [P  0.0001] for established RA), as
well as self-reported depression prior to baseline (27%
versus 14% [P  0.0001] for early RA; 28% versus 16%
[P  0.0001] for established RA).
Although in early RA significantly more women had
been hospitalized for RA before baseline (0.8% for men
versus 2.3% for women; P  0.009), more men had had
joint surgery (24% versus 17%; P  0.0001); these differ-
ences were not found in established RA. Men and women
did not differ in their use of strong DMARDs or predni-
sone, although in the established RA group more men were
using prednisone (35% versus 32%; P  0.01). On the
other hand, weak DMARDs (hydroxychloroquine, minocy-
cline) (14% versus 9%; P  0.0001 for early RA and 15%
versus 11%; P  0.0002 for established RA) and anti-TNF
therapy (26% versus 21%; P  0.003 for early RA and 56%
versus 50%; P  0.0001 for established RA) were more
commonly used among women. Mean  SD duration of
followup did not differ between men and women (13.7 
7.8 versus 13.5  7.9 [P  0.50] for early RA; 16.3  9.0
versus 15.6  8.8 [P  0.0001] for established RA).
Stepwise multivariate logistic regression. Sustained re-
mission. A total of 771 patients achieved sustained CDAI
remission during the course of the study (Figure 1). In the
logistic regression model with CDAI sustained remission
as the outcome variable, male sex was a significant predic-
tor of sustained remission in early RA (unadjusted odds
ratio [OR] 1.43, 95% confidence interval [95% CI] 1.12–
Table 1. Disease characteristics at baseline in the CORRONA cohort of RA patients*
Characteristic








(n  5,630) P
Age, years 57.9  12.6 53.7  14.2  0.0001 60.0  11.8 57.9  12.8  0.0001
Disease duration, years 0.9  0.8 0.9  0.8 0.83 12.9  9.1 13.9  9.8  0.0001
White race, no. (%) 658 (87.3) 1,868 (82.6) 0.002 1,435 (86.9) 4,654 (82.7)  0.0001
Married, no. (%) 596 (79.9) 1,380 (61.5)  0.0001 1,266 (77.4) 3,494 (62.8)  0.0001
Work status, no. (%)
Full time 413 (55.1) 987 (43.9)  0.0001 657 (40.3) 1,794 (32.2)  0.0001
Part time/not working outside home/student 97 (12.9) 673 (30.0) 268 (16.5) 1,627 (29.2)
Disabled/retired 240 (32.0) 586 (26.1) 704 (43.2) 2,145 (38.5)
Subcutaneous nodules ever, no. (%) 66 (8.8) 146 (6.5) 0.03 455 (27.6) 1,302 (23.2) 0.0002
Rheumatoid factor seropositivity, no. (%) 351 (73.3) 923 (69.9) 0.16 745 (79.3) 2,305 (77.1) 0.16
Erosions, no. (%) 9 (1.8) 43 (2.8) 0.56 103 (9.3) 427 (10.8) 0.22
ESR, mm/hour 23.5  23.4 25.6  21.3 0.12 20.3  19.6 26.7  22.0  0.0001
Tender joint count 4.9  6.0 6.1  6.5  0.0001 4.4  5.6 5.0  6.0 0.0004
Swollen joint count 6.3  6.5 6.1  6.2 0.48 5.5  5.7 5.3  5.6 0.31
CDAI 17.4  13.2 18.7  13.5 0.02 15.8  12.0 16.6  12.3 0.02
Morning stiffness, hours 1.6  3.5 1.6  2.9 0.92 1.2  2.3 1.1  1.8 0.29
Physician global VAS 29.5  20.9 31.0  21.0 0.66 26.8  20.2 28.1  20.8 0.02
Patient global VAS 32.6  25.4 35.2  25.9 0.02 32.9  24.5 35.0  25.4 0.005
Patient pain VAS 35.2  26.1 37.8  27.0 0.02 34.1  24.9 36.8  26.0  0.0001
M-HAQ 0.36  0.45 0.41  0.45 0.008 0.35  0.43 0.42  0.47  0.0001
Self-reported depression, no. (%) 106 (14.3) 594 (27.0)  0.0001 255 (15.8) 1,508 (27.6)  0.0001
MI or stroke before BL, no. (%) 59 (7.8) 67 (3.0)  0.0001 169 (10.2) 205 (3.6)  0.0001
Diabetes mellitus before BL, no. (%) 59 (7.8) 142 (6.3) 0.14 160 (9.7) 395 (7.0) 0.0003
Background use, no. (%)
Prednisone use 289 (38.3) 798 (35.3) 0.13 577 (34.9) 1,782 (31.7) 0.01
TNF inhibitor use 156 (20.7) 589 (26.0) 0.003 819 (49.6) 3,177 (56.4)  0.0001
“Strong” DMARD use 457 (60.6) 1,418 (62.7) 0.31 1,064 (64.4) 3,671 (65.2) 0.55
“Weak” DMARD use 65 (8.6) 322 (14.2)  0.0001 184 (11.1) 834 (14.8) 0.0002
Previously hospitalized for RA, no. (%) 6 (0.8) 52 (2.3) 0.009 97 (5.9) 294 (5.2) 0.31
Previous joint surgery, no. (%) 183 (24.3) 383 (17.0)  0.0001 572 (34.8) 1,945 (34.7) 0.96
Length of followup, quarters 13.7  7.8 13.5  7.9 0.70 16.3  9.0 15.6  8.8 0.009
* Values are the mean  SD unless indicated otherwise. CORRONA  Consortium of Rheumatology Researchers of North America; RA  rheumatoid
arthritis; ESR  erythrocyte sedimentation rate; CDAI  Clinical Disease Activity Index; VAS  visual analog scale; M-HAQ  modified Health
Assessment Questionnaire; MI  myocardial infarction; BL  baseline; TNF  tumor necrosis factor; DMARD  disease-modifying antirheumatic drug.
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1.82, P  0.004) but not in established RA (unadjusted OR
1.02, 95% CI 0.81–1.29, P  0.84). As shown in Table 2,
after adjusting for covariates in the multivariate model,
male sex was still associated with an increased odds for
sustained remission in early RA (OR 1.38, 95% CI 1.07–
1.78, P  0.01), whereas in established RA, no association
was observed with sex (OR 0.93, 95% CI 0.72–1.18, P 
0.55). In early RA, covariates that were indicative of more
severe disease were significantly and inversely associated
with sustained remission, i.e., self-reported depression,
presence of nodules, use of anti-TNF therapy, and longer
RA duration. Ethnicity did not influence remission status.
Point remission (among those not achieving sustained
remission). Among the patients who did not achieve sus-
tained remission, 531 achieved point remission. As shown
in Table 3 in the stepwise logistic regression model, male
sex was inversely associated with point remission among
established RA patients (unadjusted OR 0.70, 95% CI
0.52–0.92, P  0.01), but not in the early RA group (un-
adjusted OR 0.88, 95% CI 0.61–1.24, P  0.48). After
adjusting for covariates, male sex was still inversely asso-
ciated with point remission in established RA (OR 0.65,
95% CI 0.48–0.87, P  0.005), but not early RA (OR 0.85,
95% CI 0.59–1.21, P  0.39).
DISCUSSION
In this large observational cohort of RA patients from the
CORRONA database, male sex was a significant and inde-
pendent predictor for sustained CDAI remission. This as-
sociation was seen in early RA and was not observed in
established RA. Since there were a number of variables
associated with sex at baseline in this cohort, such that
women had more severe baseline disease, we identified
among them those that we believed could potentially in-
fluence remission and adjusted for them in the logistic
regression models. These included baseline CDAI scores,
anti-TNF therapy, self-reported depression, pain on a
VAS, and the work status category (included as patients
who worked part time, did not work outside the home, or
were students). Adjusting for these confounders in the
logistic regression models slightly reduced the strength of
the association. Nonetheless, male sex remained signifi-
cantly and independently associated with sustained re-
mission in the early RA group. Thus, although the contri-
bution of sex was relatively small, it is most likely real and
not just a statistical artifact. Further, the smaller numbers
of men compared to women in our analyses do not, in our
opinion, change the results as they, in fact, represent a
relatively large sample of men for RA studies. Among the
patients who did not achieve sustained remission during
our study followup of this CORRONA cohort, sex did not
influence point remission in early RA, although women
were more likely to achieve point remission than men in
the established RA group.
The present study is the first to report that male sex is a
significant predictor for sustained remission in early RA in
contrast to established RA. Most previous studies on this
topic had examined the influence of sex on point remis-
sion in RA (7,9,11–13,21). However, point remission may
be limited in its clinical importance as it is based on data
from a single time point and may not be as reliable or
clinically relevant as sustained remission, which is based
on data from at least 2 time points spread over a period of
time. An association with sustained remission had been





OR (95% CI) P
RA duration 2 years
Sex† 1.38 (1.07–1.78) 0.01
Ethnicity‡ 0.99 (0.71–1.37) 0.96
Baseline CDAI 1.00 (0.99–1.01) 0.65
RA duration 0.75 (0.64–0.89) 0.0007
Depression (self-reported) 0.40 (0.28–0.58)  0.0001
TNF inhibitor use 0.65 (0.47–0.89) 0.008
Subcutaneous nodules 0.41 (0.20–0.76) 0.008
Pain VAS 0.99 (0.98–0.99)  0.0001
RA duration 2 years
Sex† 0.93 (0.75–1.22) 0.55
Ethnicity‡ 0.91 (0.69–1.20) 0.53
Baseline CDAI 0.99 (0.97–0.99) 0.03
RA duration 0.98 (0.97–1.00) 0.007
Depression 0.71 (0.51–0.86) 0.01
Prednisone use 0.66 (0.50–0.81) 0.0009
Subcutaneous nodules 0.53 (0.42–0.76)  0.0001
Pain VAS 0.99 (0.98–0.99)  0.0001
* All covariates adjusted for in the final model are listed as inde-
pendent variables. CDAI  Clinical Disease Activity Index; OR 
odds ratio; 95% CI  95% confidence interval; RA  rheumatoid
arthritis; TNF  tumor necrosis factor; VAS  visual analog scale.
† The referent group for this variable was female sex.
‡ The referent group for this variable was white race.
Table 3. Multivariate logistic regression of sex on





OR (95% CI) P
RA duration 2 years
Sex† 0.86 (0.59–1.21) 0.39
Ethnicity‡ 0.97 (0.62–1.45) 0.88
Baseline CDAI 0.99 (0.98–1.00) 0.06
Prednisone use 1.45 (1.06–1.97) 0.02
RA duration 2 years
Sex† 0.65 (0.48–0.87) 0.005
Ethnicity‡ 0.82 (0.58–1.13) 0.23
Baseline CDAI 0.99 (0.98–1.00) 0.06
Length of followup 1.01 (1.00–1.03) 0.03
RA duration 0.98 (0.97–1.00) 0.01
Pain VAS 0.99 (0.98–0.99)  0.0001
* All covariates adjusted for in the final model are listed as inde-
pendent variables. CDAI  Clinical Disease Activity Index; OR 
odds ratio; 95% CI  95% confidence interval; RA  rheumatoid
arthritis; VAS  visual analog scale.
† The referent group for this variable was female sex.
‡ The referent group for this variable was white race.
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reported in an early RA cohort (8), but similar investiga-
tions in established RA cohorts had not been performed.
Despite variations in the definitions of remission used in
the different studies based on the DAS44, DAS28, simpli-
fied DAI, CDAI, and ACR criteria (13), our findings are in
agreement with previous reports of male sex being a sig-
nificant predictor of remission in RA (4,6–13). We also
previously examined response measures other than remis-
sion in men and women with RA, including European
League Against Rheumatism (EULAR) responses in 2 other
RA cohorts (5,22), and found that men had better EULAR
responses compared to women in early RA and not estab-
lished RA (22). Thus, our findings of increased sustained
remission among men in early RA and not established RA
in the CORRONA cohort are in agreement with those pre-
vious findings and support the finding that men have
better responses irrespective of the treatment outcome un-
der study, including sustained remission.
In general, sex-specific investigations as presented here
have not been addressed in most studies of RA remission.
Among the few studies that have examined sex as a pre-
dictor for remission, either as a primary predictor or as a
covariate in the multivariate analyses, only 2 did not find
an association between sex and remission (14,15). This
could be due to the very small sample sizes (195 and 105
patients, respectively) in both of these studies. In the large
multinational Quantitative Patient Questionnaires in Stan-
dard Monitoring of Patients with RA study, although it
was shown that men achieved remission more often than
women irrespective of the definition of remission (13), it
has also been postulated that sex differences in RA disease
activity may be the result of a sex bias in reporting of
disease activity measures (21). One could also speculate
other possibilities to explain the data, including immuno-
logic response differences, drug dosing differences, and
genetic differences between men and women. Our data do
not allow us to differentiate among these possibilities.
It is as yet unclear why men are more likely than women
to achieve sustained remission in early RA and not estab-
lished RA. As we and others have demonstrated, patients
with shorter RA duration, i.e., early RA, are more likely to
achieve remission (3,23). It is therefore quite plausible that
treatment responses and rates of remission may be of a
smaller magnitude among both men and women in estab-
lished RA, thus making the sex differences less apparent,
especially since the difference in response observed be-
tween men and women in early RA is in itself relatively
small. The increased odds of sustained remission among
men in early RA is nevertheless intriguing and has not yet
been explained. Presumably, such differences in treatment
response between men and women could arise as a result
of genetic, physiologic, immunologic, or even psychoso-
cial differences between the sexes. In the multivariate
regression models, self-reported depression, subcutaneous
nodules, and anti-TNF therapy were significant predictors
for no remission. It may be expected that more severe
disease, as indicated by subcutaneous nodules and anti-
TNF therapy, and being depressed would reduce the prob-
ability of remission as suggested from previous studies
(24–26). Even after these confounders were adjusted in the
logistic regression models, male sex was still a significant
and independent predictor of sustained remission in the
CORRONA cohort. Furthermore, there were no differences
between men and women in the effect of self-reported
depression, anti-TNF therapy, or prednisone on sustained
remission in the CORRONA cohort (data not shown). This
suggests that there are additional sex-specific factors in
operation in influencing the chances of sustained remis-
sion in RA, especially in the first two years after diagnosis.
The range of possible physiologic, immunologic, and psy-
chological factors that may differ between men and
women and that could influence remission in RA is vast,
and identification of the specific culprit responsible for the
increased sustained remission among men in early RA is
beyond the scope of this study.
There may also be “gender” differences contributing to
men being more likely to undergo sustained remission. For
example, CDAI scores, and hence CDAI remission, are
highly dependent on pain perception. We could speculate
that men may have a higher threshold for reporting joint
tenderness and global health in the early stages of the
disease, but as disease duration increases, adaptive mech-
anisms relating to pain perception may be in operation,
leading to more similar reporting of symptoms between
men and women. Regarding patients who did not achieve
sustained remission, however, we cannot explain our find-
ings of why women should be more likely to achieve point
remission in established RA and not in early RA.
The large number of sites, relatively long followup, both
physician-derived and patient-derived outcomes, and use
of a “real-life” cohort represent significant strengths of the
study. There are also some limitations in this study. Our
results demonstrate an association between male sex and
sustained remission in early RA; however, the available
data and observational nature of the CORRONA cohort do
not allow us to determine the cause of this association.
Although our database size allows us to adjust for many
potential confounders, the possibility remains that there
may be additional unknown confounders that we have not
recorded and so could not adjust for in the multivariate
models, including the true causative agent. We used CDAI
remission as our outcome measure because data on the
CDAI were available on a larger number of patients in the
CORRONA database and because CDAI remission is a
more rigorous definition of remission. Although there is
currently no gold standard for assessing clinical remission
in RA, comparisons of measures of remission have shown
that the CDAI remission criteria are more stringent than
those for DAS28 or modified ACR remission, allowing for
less residual disease activity (27). Therefore, we feel that
the CDAI remission is an appropriate measure for the
primary outcome in this study.
Given the large sample size of the CORRONA cohort, it
is possible that statistical significance may have been
achieved as a result of the large sample size without re-
flecting clinical significance, as seen for some of the base-
line comparisons in Table 1. Our main finding that men
are more likely to achieve sustained remission does not,
however, appear to be the result of a statistical artifact.
Nonetheless, we would like to point out that the number of
men in our study cohort, although large for RA studies, is
not large enough to make the results irrefutable. The data
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analyzed in the present study were collected at over 100
different sites by different rheumatologists who are part of
the CORRONA network. Some subtle variation in the clin-
ical measures recorded may have been introduced as a
result of assessment by different rheumatologists, or there
may have been differences in routine clinical care and
standard treatment practices specific to certain recruit-
ment sites. At the same time, that same large number of
sites and physicians mitigates against a systematic differ-
ence in these areas. The CORRONA cohort consists of
patients in routine clinical care enrolled since 2001, and
the inclusion criteria only required that the patients satisfy
the 1987 ACR criteria for RA and were being treated by a
rheumatologist participating in the CORRONA network.
Therefore, within the cohort, patients had variable RA
duration and had been on various therapies for various
lengths of time. We could not adjust for duration of ther-
apy in the analyses presented as we did not have accurate
data on drug usage before cohort enrollment. As a proxy
for treatment duration, we adjusted for RA duration under
the assumption that treatment started soon after diagnosis.
In summary, within the large real-life CORRONA cohort
of RA patients, men were more likely to achieve sustained
remission compared to women in early RA, although not
in established RA.
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